Special Issue

Targeting Epigenetic Regulation for Cancer Therapy

Message from the Guest Editors

This Special Issue aims to explore the complex network of epigenetic factors beyond DNA methyltransferases (DNMTs) that regulate gene activity, genome stability, and cellular identity. We welcome contributions from a broad range of biological systems and disciplines that address how different epigenetic mechanisms function. interact, and contribute to physiological or pathological processes, with a particular emphasis on their implications for cancer biology and therapy. We invite original research articles, reviews, and perspective papers that investigate epigenetic mechanisms beyond DNMTs, including histone-modifying enzymes, chromatin remodelers, and non-coding RNAs. Both experimental and computational studies are encouraged, as well as work spanning molecular. cellular, organismal, or environmental levels. Submissions that explore translational aspects—such as epigenetic biomarkers or the development of epigenetic drugs for cancer therapy—are of particular interest. All topics related to the central theme of epigenetic regulation—including novel insights, emerging technologies, comparative analyses, and interdisciplinary approaches—are welcome.

Guest Editors

Dr. Bence Raposa

Institute of Basics of Health Sciences, Midwifery and Health Visiting, Faculty of Health Sciences, University of Pécs, Vörösmarty Mihály Str. 4, 7621 Pécs, Hungary

Dr. John M. Macharia

Faculty of Health Sciences, University of Pécs, Vörösmarty Mihály Str. 4, 7621 Pécs, Hungary

Deadline for manuscript submissions

25 February 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/244017

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

